Samcheondang Pharmaceutical (000250) extended its decline on the 24th, hitting a new 52-week low during the trading session. As the domestic stock market plunged due to geopolitical tensions between the United States and Iran, market attention is now focused on the stock's direction next week.

In the regular trading session, Samcheondang Pharmaceutical closed at 148,800 won, down 10.42% (17,300 won) from the previous trading day. During the session, the stock fell to as low as 141,500 won, marking a new 52-week low, before partially recovering some of its losses but ultimately closing in the 140,000-won range.

On the same day, the KOSPI closed at 6,690.62, down 406.27 points (-5.72%) from the previous trading day, while the KOSDAQ closed at 748.22, down 42.06 points (-5.32%), as investor sentiment shrank significantly. This was the result of a spreading risk-asset aversion sentiment driven by heightened tensions between the United States and Iran. Amid the broader market weakness, the biotech sector also faced selling pressure, and Samcheondang Pharmaceutical widened its losses as well. The recent expansion of volatility in global financial markets and the risk-asset aversion sentiment adding pressure to the overall domestic stock market are also interpreted as factors behind the stock's decline.

The market is closely watching Samcheondang Pharmaceutical's stock price trend next week. Whether bargain-hunting buying will flow in after the intraday low, or whether a phase of continued market volatility and further direction-seeking will persist, is cited as the key focal point for the coming week.

[This article is not intended to solicit investment. All final investment decisions and responsibilities lie with the investor.]